YPSILÓS Release New Range of Full-Spectrum Cannabinoid Products
28 déc. 2023 09h00 HE
|
YPSILÓS
Naxxar, Malta, Dec. 28, 2023 (GLOBE NEWSWIRE) -- YPSILOS, a trailblazer in the cannabinoid industry since 2021, is proud to announce its new range of top-tier full-spectrum cannabinoid products,...
Astrotech Presents the First Process Control System for Cannabinoid Oil Distillation Systems
27 nov. 2023 21h04 HE
|
Astrotech Corporation
AUSTIN, Texas, Nov. 27, 2023 (GLOBE NEWSWIRE) -- via IBN - Astrotech Corporation (NASDAQ: ASTC) ("Astrotech" or the "Company") and its wholly owned subsidiary, AgLAB, Inc., announce the presentation...
Federal Court of Australia Approves Incannex’s Re-Domiciliation and Lodgement of Court Orders With ASIC
16 nov. 2023 08h30 HE
|
Incannex Healthcare
MELBOURNE, Australia, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL) (the “Company” or “Incannex”) is pleased to announce that the Federal Court of Australia...
Vivimu Unveils Groundbreaking Compassionate Care Initiative: A 1 Billion MG Hemp-Derived Cannabinoid Giveaway Program
02 oct. 2023 09h00 HE
|
Vivimu
GOLDEN, Colo., Oct. 02, 2023 (GLOBE NEWSWIRE) -- In a bold move to democratize access to quality hemp-derived products, Vivimu.com has unveiled its "1 Billion MG Compassionate Care Initiative". This...
Clarion Clinics Begins Accepting Registrations for Psychedelic Treatment Interest as Part of Pre-Screening in Readiness for Opening
08 août 2023 08h00 HE
|
Incannex Healthcare
Highlights: Incannex subsidiary, Clarion Clinics Group Pty Ltd (Clarion) begins accepting registrations of interest in its psychedelic-assisted therapy (PAT) treatments ahead of planned Q3...
SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.
01 août 2023 09h00 HE
|
SciSparc Ltd
TEL AVIV, Israel, Aug. 01, 2023 (GLOBE NEWSWIRE) -- The new U.S. patent application is for the use of the psychedelic molecule 3-MMC and SciSparc's Palmitoylethanolamide to treat dyskinesia and...
Incannex Healthcare June 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement
28 juil. 2023 07h30 HE
|
Incannex Healthcare
MELBOURNE, Australia, July 28, 2023 (GLOBE NEWSWIRE) -- Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL), (‘Incannex’ or the ‘Company’), is...
Incannex Submits IND Application to the US FDA for IHL-42X for Obstructive Sleep Apnoea
21 juil. 2023 09h09 HE
|
Incannex Healthcare
MELBOURNE, Australia, July 21, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique...
Incannex Receives HREC Approval for Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid Arthritis
13 juil. 2023 08h00 HE
|
Incannex Healthcare
Highlights: Incannex has received approval from HREC for the lead site, Emeritus Research, Camberwell, VIC for the Phase 2, Blinded, Placebo Controlled Clinical Trial to Determine the Effect on Pain...
Incannex Announces Intention to Redomicile to United States, List all Shares on Nasdaq
10 juil. 2023 07h30 HE
|
Incannex Healthcare
Highlights: Incannex to redomicile to the United States via a Scheme of Arrangement pursuant to Australian lawA newly formed Delaware corporation (Incannex Healthcare Inc.) will become the ultimate...